Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy.

Anna De Bona(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), Aurelia Guzzo, Laura Galli(Vita-Salute San Raffaele University), Laura Alagna(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Giulia Gallotta(Vita-Salute San Raffaele University)
PubMed
July 1, 2007
Cited by 7

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2001|173